The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)
The Epidemiology of Burkitt lymphoma in East African children and minors (EMBLEM) is a research study sponsored by the Intramural Research program of the National Cancer Institute under Protocol #: 10-C-N133 during 2010-2016 to comprehensively investigate infections, immunological, and genetic risk factors of Burkitt lymphoma (BL).See more details on our Study Summary page.
October 11, 2020 | Nature Research Cancer Community
August 11, 2020 | Medical Xpress
March 3, 2020 | Molecular Biology and Evolution
by Kirimunda et al.
by Peprah et al.
EMBLEM is a case control study of childhood Burkitt lymphoma (BL) designed to investigate risk factors of BL in malaria-endemic areas of Uganda, Tanzania, and Kenya.
EMBLEM was designed to enroll representative cases and controls (0-15 years) from defined geographical areas and use questionnaire, serological, and genetic methods to study BL.
Although identified as co-factors of BL more than 50 years ago, the malaria phenotypes and EBV variants associated with BL are not known. EMBLEM seeks to answer these questions to pave the way for interventions.
The use of genetic studies promises to unlock the biology of disease and point to therapeutic targets. EMBLEM is applying genomic methods to define BL subtypes, discover risk factors, and identify biomarkers.